

Date: 13.11.2025

To,  
Department of Corporate Services,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

**Scrip Code: 524748**

Dear Sir/Madam,

**Sub: Outcome of Board Meeting**

**Ref: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.**

Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we hereby inform you that the Board of Directors of the Company, at its Meeting held today, i.e. Thursday 13<sup>th</sup> November, 2025, inter alia, considered and approved followings:

01. Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025 along with the Limited Review Report of the Statutory Auditors. Please find enclosed herewith Unaudited Financial Results along with Limited Review Report for the quarter and half year ended September 30, 2025.
02. Resignation Letter received from Ms. Khushbu Prakashbhai Patel, Company Secretary and Compliance Officer of the Company from the post of Company Secretary & Compliance Officer of the Company with effect from closure of business hours on Tuesday, 16<sup>th</sup> December, 2025. The Board has accepted her resignation at the meeting held today i.e 13<sup>th</sup> November, 2025. Disclosure required pursuant to Regulation 30 of the Listing Regulations read with Para A of Part A of Schedule III to the Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 November 11, 2024 with regard to change in Directors and Key Managerial Personnel is given herein under as annexure.

The meeting of the Board of Directors commenced at 11:30 A.M and concluded at 12:30 P.M.

Kindly take the same on your record.

Thanking you,

Yours truly,  
For Link Pharma Chem Limited

Rishikesh Thakur  
Managing Director  
DIN: 08777265

Encl: As above

---

**REGISTERED OFFICE:**

Plot No. 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)  
Tel. (O) 87806 04490 E-Mail: linkpharmacs@gmail.com  
CIN: L24230GJ1984PLC007540 Website: www.linkpharmachem.co.in

**Independent Auditor's Review Report on Unaudited Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Link Pharma Chem Limited**

1. We have reviewed the accompanying Statement of Unaudited Financial results of **Link Pharma Chem Limited** ("the Company") for the quarter ended 30th September, 2025 and the year to date results for the period from 1st April, 2025 to 30th September, 2025 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

**For CNK & Associates LLP**

Chartered Accountants

Firm Registration No. 101961W/W-100036



Pareen Shah

Partner

Membership No. 125011

Place: Vadodara

Date: 13<sup>th</sup> November, 2025

UDIN:25125011BMGZAX9130



The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: [www.cnkindia.com](http://www.cnkindia.com)

VADODARA | MUMBAI | CHENNAI | AHMEDABAD | GIFT CITY | BENGALURU | DELHI | PUNE | DUBAI | ABU DHABI



# Link

## Pharma Chem Ltd.

ISO-9001 - 2015 - ISO-14001 - 2015

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025

(Rs in Lakhs)

Sr. No.	Particulars	Quarter ended			Half year Ended		Year ended
		30th September 2025	30th June 2025	30th September 2024	30th September 2025	30th September 2024	31st March 2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	629.32	781.48	479.82	1,410.80	1,364.45	2,543.34
	Other income	4.78	20.92	35.86	25.70	63.02	18.65
	<b>Total Income (A)</b>	<b>634.10</b>	<b>802.40</b>	<b>515.68</b>	<b>1,436.50</b>	<b>1,427.47</b>	<b>2,561.99</b>
2	<b>Expenses:</b>						
	Cost of materials consumed	257.18	269.69	260.61	526.87	760.17	1,121.75
	Changes in inventories of finished goods and work-in-progress	(38.07)	61.48	(70.56)	23.42	(62.93)	132.72
	Employee benefits expense	141.39	153.02	142.06	294.41	272.87	539.22
	Finance costs	12.86	10.40	20.85	23.26	42.89	77.55
	Depreciation and amortization expense	24.77	23.91	23.59	48.68	47.13	94.29
	Power and Fuel	94.20	86.36	81.24	180.56	165.58	310.82
	Other Expenses	140.55	146.56	96.80	287.11	204.64	425.90
	<b>Total expenses (B)</b>	<b>632.87</b>	<b>751.43</b>	<b>554.59</b>	<b>1,384.31</b>	<b>1,430.35</b>	<b>2,702.24</b>
3	<b>(Loss)/Profit before tax (C) = (A-B)</b>	<b>1.23</b>	<b>50.97</b>	<b>(38.91)</b>	<b>52.19</b>	<b>(2.88)</b>	<b>(140.25)</b>
4	<b>Tax expense:</b>						
	(1) Current tax	-	-	-	-	-	-
	(2) Short/(Excess) Provision of tax relating to earlier Year	-	-	-	-	-	2.56
	(3) Deferred tax	(0.33)	10.78	(8.28)	10.46	(1.89)	(40.08)
	<b>Total tax expense (D)</b>	<b>(0.33)</b>	<b>10.78</b>	<b>(8.28)</b>	<b>10.46</b>	<b>(1.89)</b>	<b>(37.52)</b>
5	<b>(Loss)/Profit for the year/period (E) = (C-D)</b>	<b>1.56</b>	<b>40.19</b>	<b>(30.63)</b>	<b>41.73</b>	<b>(0.99)</b>	<b>(102.73)</b>
6	<b>Other Comprehensive Income</b>						
	<b>Items that will not be reclassified to profit or loss</b>						
	Net fair value gain on equity instruments through Other Comprehensive Income	(0.05)	0.32	0.15	0.26	0.30	(0.06)
	Remeasurement (loss) / gain of the defined benefit plan	(0.65)	(0.65)	1.02	(1.30)	2.04	(2.60)
	Income tax effect on above	0.15	0.18	(0.32)	0.33	(0.64)	0.73
	<b>Total other comprehensive income for the year/period, net of tax (F)</b>	<b>(0.55)</b>	<b>(0.15)</b>	<b>0.85</b>	<b>(0.70)</b>	<b>1.71</b>	<b>(1.93)</b>
7	<b>Total comprehensive income for the year/period (Net of Tax) (E+F)</b>	<b>1.01</b>	<b>40.04</b>	<b>(29.78)</b>	<b>41.03</b>	<b>0.72</b>	<b>(104.66)</b>
8	Paid up Equity share capital of Rs 10 each	444.06	444.06	444.06	444.06	444.06	444.06
9	Other Equity						822.15
10	Earnings per equity share (FV of Rs. 10) (Rs.)						
	Basic and Diluted	0.03	0.91	(0.69)	0.94	(0.02)	(2.31)



REGISTERED OFFICE : Plot No. 161, 161/1, 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara, (Gujarat), (India).

Tel. (O) 87806 04490 E-Mail : linkpharmalimited@gmail.com

CIN: L24230GJ1984PLC007540 www.linkpharmachem.co.in





# Link

## Pharma Chem Ltd.

ISO-9001 - 2015 - ISO-14001 - 2015

**Notes:**

- 1 The above financial results for the Quarter and Half year ended on September 30, 2025 have been reviewed by Statutory auditors, recommended by the Audit Committee and have been approved and were taken on record by the Board of Directors at its meeting held on November 13th, 2025.
- 2 The Company's operations fall under single segment namely "Manufacture and Sale of Chemicals".
- 3 As per the Ind AS 109 - 'Financial Instruments', the investment of the Company are valued at market prices and the difference between the cost and market value of the investments are accounted as part of Other Income. The break up of the reported figures are arrived as per working given hereunder.

Particulars	Quarter ended			Half year Ended		Year ended
	30th September 2025	30th June 2025	30th September 2024	30th September 2025	30th September 2024	31st March 2025
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Other income (A)	4.78	20.92	35.86	25.70	63.02	18.65
Fair value Net Gain/(loss) arising on financial asset designated as at FVTPL (B)	4.18	18.96	34.13	23.14	57.35	9.68
<b>Adjusted Other Income (A-B)</b>	<b>0.60</b>	<b>1.96</b>	<b>1.73</b>	<b>2.55</b>	<b>5.67</b>	<b>8.97</b>

Date : 13th November, 2025  
Place : Vadodara



For Link Pharma Chem Limited

Rishikesh Satish Thakur  
Managing Director  
(DIN: 08777265)



# Link

## Pharma Chem Ltd.

ISO-9001 - 2015 - ISO-14001 - 2015

### STATEMENT OF ASSETS AND LIABILITIES

(Rs in Lakhs)

Particulars	As at 30th September, 2025 (Unaudited)	As at 31st March, 2025 (Audited)
<b>I. ASSETS</b>		
<b>1. NON CURRENT ASSETS</b>		
(a) Property, Plant and Equipment		
(b) Capital work in progress	993.57	927.74
(c) Financial Assets	9.17	-
(i) Investments		
(ii) Other financial assets	252.70	205.53
(d) Deferred tax assets (Net)	44.68	39.01
(e) Other non-current assets	13.09	23.21
<b>Total non-current assets</b>	32.89	17.91
<b>2. CURRENT ASSETS</b>	<b>1,346.10</b>	<b>1,213.40</b>
(a) Inventories		
(b) Financial Assets	525.96	573.65
(i) Trade receivables		
(ii) Cash and cash equivalents	511.16	501.72
(iii) Loans	156.57	6.45
(c) Other current assets	3.32	0.90
<b>Total current assets</b>	23.32	33.18
<b>Total Assets</b>	<b>1,220.33</b>	<b>1,115.91</b>
	<b>2,566.43</b>	<b>2,329.31</b>
<b>II. EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share capital		
(b) Other Equity	444.06	444.06
<b>Total Equity</b>	863.17	822.15
<b>Liabilities</b>	<b>1,307.23</b>	<b>1,266.21</b>
<b>Non-current liabilities</b>		
(a) Financial liabilities		
Borrowings		
(b) Provisions	226.81	41.74
<b>Total non-current liabilities</b>	19.98	16.18
<b>Current liabilities</b>	<b>246.79</b>	<b>57.92</b>
(a) Financial liabilities		
(i) Borrowings		
(ii) Trade payables	582.52	536.50
(A) Total outstanding dues of Micro enterprises and Small Enterprises	10.18	75.80
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	213.24	272.46
(iii) Other financial liabilities		
(b) Other current liabilities	2.37	4.58
(c) Short term Provision	142.06	69.62
<b>Total current liabilities</b>	62.04	46.22
<b>Total Equity and liabilities</b>	<b>1,012.41</b>	<b>1,005.18</b>
	<b>2,566.43</b>	<b>2,329.31</b>

Date : 13th November, 2025  
Place : Vadodara



For Link Pharma Chem Limited

Rishikesh Satish Thakur  
Managing Director  
(DIN: 08777265)

REGISTERED OFFICE : Plot No. 161, 161/1, 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara, (Gujarat), (India).

Tel. (O) 87806 04490 E-Mail : linkpharmalimited@gmail.com

CIN: L24230GJ1984PLC007540 www.linkpharmachem.co.in



# Link

## Pharma Chem Ltd.

ISO-9001 - 2015 - ISO-14001 - 2015

### STATEMENT OF AUDITED CASH FLOW FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2025

(Rs in Lakhs)

Particulars	For the Half year ended Sept. 30, 2025 (Unaudited)	For the Half year ended Sept. 30, 2024 (Unaudited)	For the year ended March 31, 2025 (Audited)
<b>A. Cash Flow From Operating Activities</b>			
Net profit before taxation	52.19	(2.88)	(140.25)
Adjustments For :			
Depreciation and amortization expense	48.68	47.13	94.29
Net gain on sale of investments	-	-	(2.78)
Fair valuation of Investments through FVTPL	(23.14)	(57.35)	(9.68)
Remeasurement (loss) / gain of the defined benefit plan	(1.30)	2.04	(2.60)
Provision for Doubtful Debts	13.00	-	2.34
Dividend Income	(0.42)	(1.27)	(1.51)
Interest income	(2.13)	(4.40)	(4.68)
Finance cost	23.26	42.89	77.55
Net Adjustments	57.95	29.03	152.92
<b>Operating Profit Before Working Capital Changes</b>	<b>110.15</b>	<b>26.16</b>	<b>12.68</b>
Adjustments For :			
(Increase)/Decrease in inventories	47.69	(54.84)	47.15
(Increase)/Decrease in trade receivables	3.56	162.19	11.10
(Increase)/Decrease in financial assets	(2.42)	20.47	20.57
(Increase)/Decrease in other assets	3.46	(32.03)	(26.73)
Increase/(Decrease) in trade and other payables	(34.97)	153.81	200.48
<b>Working Capital Changes</b>	<b>17.32</b>	<b>249.60</b>	<b>252.56</b>
<b>Cash Generated From Operations</b>	<b>127.47</b>	<b>275.75</b>	<b>265.24</b>
Taxes Paid (Net)	(8.58)	(6.83)	3.35
<b>Net Cash From Operating Activities (A)</b>	<b>118.89</b>	<b>268.93</b>	<b>268.59</b>
<b>B. Cash Flow From Investing Activities</b>			
Purchase of property, plant & equipment	(125.89)	(14.35)	(25.72)
Purchase of investments	(47.17)	(11.88)	(35.64)
Proceeds from sale of investments	-	-	135.77
Dividend Income	-	1.27	1.51
(Increase)/Decrease in bank deposits	(5.67)	0.37	72.32
Interest received	2.13	4.40	4.68
<b>Net Cash Used in Investing Activities (B)</b>	<b>(176.59)</b>	<b>(20.19)</b>	<b>152.93</b>
<b>C. Cash Flow From Financing Activities</b>			
Proceeds from Long term borrowings	78.28	-	-
Repayment of long term borrowings	106.79	(55.43)	(74.44)
Proceeds/(repayment) of short term borrowings (Net)	46.02	(47.40)	(269.50)
Finance cost paid	(23.26)	(42.89)	(77.55)
<b>Net Cash Used In Financing Activities (C)</b>	<b>207.83</b>	<b>(145.72)</b>	<b>(421.49)</b>
Net (decrease)/Increase In Cash and Cash Equivalents (A+B+C)	150.12	103.02	0.03
Cash and Cash Equivalents at Beginning of Year	6.45	6.42	6.42
<b>Cash and Cash Equivalents at the End of Year</b>	<b>156.57</b>	<b>109.44</b>	<b>6.45</b>

Date : 13th November, 2025  
Place : Vadodara



For Link Pharma Chem Limited

Rishikesh Satish Thakur  
Managing Director  
(DIN: 08777265)

REGISTERED OFFICE : Plot No. 161, 161/1, 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara, (Gujarat), (India).

Tel. (O) 87806 04490 E-Mail : linkpharmalimited@gmail.com

CIN: L24230GJ1984PLC007540 www.linkpharmachem.co.in

Annexure

Details required under Regulation 30 of SEBI (LODR) Regulations, 2015  
Pursuant to SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 November 11, 2024.

Sr. No.	Disclosure Requirement	Details
01.	Reason for change, viz. <del>appointment, resignation, removal, death or otherwise</del>	Resignation of Ms. Khushbu Prakashbhai Patel from the post of Company Secretary and Compliance Officer of the Company due to better prospect outside the organization.
02.	Date of <del>appointment</del> / cessation (as applicable) & term of appointment	She will be relieved from her duties as Company Secretary and Compliance Officer, Key Managerial Personnel of the Company with effect from closure of business hours on Tuesday, 16th December, 2025.
03.	Brief profile	Not Applicable
04.	Disclosure of relationships between Directors (in case of appointment of a director)	Not Applicable

**REGISTERED OFFICE:**

Plot No. 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)  
Tel. (O) 87806 04490 E-Mail: linkpharmacs@gmail.com  
CIN: L24230GJ1984PLC007540 Website: www.linkpharmachem.co.in